265 related articles for article (PubMed ID: 31464894)
1. The role of 18F-FDG PET/CT in management of paraneoplastic limbic encephalitis combined with small cell lung cancer: A case report.
Castagnoli H; Manni C; Marchesani F; Rossi G; Fattori S; Capoccetti F
Medicine (Baltimore); 2019 Aug; 98(35):e16593. PubMed ID: 31464894
[TBL] [Abstract][Full Text] [Related]
2. 18FDG PET/CT Tumoral and Neurologic Therapeutic Response in a Case of Anti-GABABR Paraneoplastic Limbic Encephalitis.
Ouvrard E; Voulleminot P; Mennecier B; Bund C; Namer IJ
Clin Nucl Med; 2023 Mar; 48(3):237-239. PubMed ID: 36723883
[TBL] [Abstract][Full Text] [Related]
3. Paraneoplastic Limbic Encephalitis Secondary to SCLC on 18F-FDG PET/CT.
Verçosa AFA; Mota IA; Flamini MEDM; Flamini RC
Clin Nucl Med; 2021 Jun; 46(6):494-496. PubMed ID: 33939650
[TBL] [Abstract][Full Text] [Related]
4. Accuracy of nodal staging by 18F-FDG-PET/CT in limited disease small-cell lung cancer.
Hockmann J; Hautzel H; Darwiche K; Eberhard W; Stuschke M; Aigner C; Herrmann K; Plönes T
Asian Cardiovasc Thorac Ann; 2023 Jul; 31(6):506-511. PubMed ID: 37438928
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of standardised uptake value (SUV
Yilmaz Demirci N; Yilmaz Ü; Biner Uslu I; Dikmen A; Yılmaz A; Erdoğan Y
Eur J Cancer Care (Engl); 2017 Sep; 26(5):. PubMed ID: 26988938
[TBL] [Abstract][Full Text] [Related]
6. Small Cell Lung Cancer Staging: Prospective Comparison of Conventional Staging Tests, FDG PET/CT, Whole-Body MRI, and Coregistered FDG PET/MRI.
Ohno Y; Yoshikawa T; Takenaka D; Koyama H; Aoyagi K; Yui M; Oshima Y; Hamabuchi N; Tanaka Y; Shigemura C; Oota S; Nomura M; Murayama K; Inui Y; Kikukawa K; Toyama H
AJR Am J Roentgenol; 2022 May; 218(5):899-908. PubMed ID: 34877872
[No Abstract] [Full Text] [Related]
7. Impact of
Al-Ibraheem A; Hirmas N; Fanti S; Paez D; Abuhijla F; Al-Rimawi D; Al-Rasheed U; Abdeljalil R; Hawari F; Alrabi K; Mansour A
BMC Med Imaging; 2021 Mar; 21(1):49. PubMed ID: 33731050
[TBL] [Abstract][Full Text] [Related]
8. Coexistence of anti-SOX1 and anti-GABAB receptor antibodies with paraneoplastic limbic encephalitis presenting with seizures and memory impairment in small cell lung cancer: A case report.
Gong S; Han Y; He E; Liu M; Fu X; Deng F
Front Immunol; 2022; 13():955170. PubMed ID: 35967304
[TBL] [Abstract][Full Text] [Related]
9. Brain 18F-FDG-PET characteristics in patients with paraneoplastic neurological syndrome and its correlation with clinical and MRI findings.
Masangkay N; Basu S; Moghbel M; Kwee T; Alavi A
Nucl Med Commun; 2014 Oct; 35(10):1038-46. PubMed ID: 25023997
[TBL] [Abstract][Full Text] [Related]
10. 18F-FDG-PET/MRI in the diagnostic work-up of limbic encephalitis.
Deuschl C; Rüber T; Ernst L; Fendler WP; Kirchner J; Mönninghoff C; Herrmann K; Quesada CM; Forsting M; Elger CE; Umutlu L
PLoS One; 2020; 15(1):e0227906. PubMed ID: 31951636
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and diagnostic value of [18F]FDG-PET/CT in restaging patients with small cell lung carcinoma: an Italian multicenter study.
Quartuccio N; Evangelista L; Alongi P; Caobelli F; Altini C; Cistaro A; Lambertini A; Schiorlin I; Popescu CE; Linguanti F; Laudicella R; Scalorbi F; Di Pierro G; Asabella AN; Cuppari L; Margotti S; Lima GM; Scalisi S; Pacella S; Kokomani A; Ciaccio A; Sturiale L; Vento A; Cardile D; Baldari S; Panareo S; Fanti S; Rubini G; Schillaci O; Chiaravalloti A;
Nucl Med Commun; 2019 Aug; 40(8):808-814. PubMed ID: 31136534
[TBL] [Abstract][Full Text] [Related]
12. 18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer: a systematic review and meta-analysis.
Machado Medeiros T; Altmayer S; Watte G; Zanon M; Basso Dias A; Henz Concatto N; Hoefel Paes J; Mattiello R; de Souza Santos F; Mohammed TL; Verma N; Hochhegger B
Eur Radiol; 2020 Jul; 30(7):3641-3649. PubMed ID: 32125513
[TBL] [Abstract][Full Text] [Related]
13. Utility of Molecular Imaging with 2-Deoxy-2-[Fluorine-18] Fluoro-DGlucose Positron Emission Tomography (18F-FDG PET) for Small Cell Lung Cancer (SCLC): A Radiation Oncology Perspective.
Sager O; Dincoglan F; Demiral S; Uysal B; Gamsiz H; Elcim Y; Gundem E; Dirican B; Beyzadeoglu M
Curr Radiopharm; 2019; 12(1):4-10. PubMed ID: 30465520
[TBL] [Abstract][Full Text] [Related]
14. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
15. Correlative imaging with (18)F-FDG PET/CT and MRI in paraneoplastic limbic encephalitis.
Maffione AM; Chondrogiannis S; Ferretti A; Al-Nahhas A; Rubello D
Clin Nucl Med; 2013 Jun; 38(6):463-4. PubMed ID: 23531769
[TBL] [Abstract][Full Text] [Related]
16. [18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches.
de Jong EE; van Elmpt W; Leijenaar RT; Hoekstra OS; Groen HJ; Smit EF; Boellaard R; van der Noort V; Troost EG; Lambin P; Dingemans AC
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):8-16. PubMed ID: 27600280
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment metabolic parameters measured by 18F-FDG-PET to predict the outcome of first-line chemotherapy in extensive-stage small-cell lung cancer.
Yu X; Zhu Y; Wang J; Song X; Zhu L; Men X; Li X; Dai D; Xu W
Nucl Med Commun; 2017 Feb; 38(2):193-200. PubMed ID: 27977537
[TBL] [Abstract][Full Text] [Related]
18. Performance Comparison Between
Kishida Y; Seki S; Yoshikawa T; Itoh T; Maniwa Y; Nishimura Y; Ohno Y
AJR Am J Roentgenol; 2018 Jul; 211(1):185-192. PubMed ID: 29667886
[TBL] [Abstract][Full Text] [Related]
19. ASL MRI and 18F-FDG-PET in autoimmune limbic encephalitis: clues from two paradigmatic cases.
Dinoto A; Cheli M; Ajčević M; Dore F; Crisafulli C; Ukmar M; Sartori A; Manganotti P
Neurol Sci; 2021 Aug; 42(8):3423-3425. PubMed ID: 33763811
[TBL] [Abstract][Full Text] [Related]
20. The role of early 18F-FDG PET/CT in therapeutic management and ongoing risk stratification of high/intermediate-risk thyroid carcinoma.
Triviño Ibáñez EM; Muros MA; Torres Vela E; Llamas Elvira JM
Endocrine; 2016 Mar; 51(3):490-8. PubMed ID: 26224589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
